Tandem Diabetes Care shares are trading higher. Stifel maintained its Buy rating on the stock and raised its PT rom $37 to $40.
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care's stock is trading higher after Stifel maintained a Buy rating and increased the price target from $37 to $40.
April 23, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel maintains a Buy rating on TNDM and raises the price target from $37 to $40, indicating a positive outlook on the stock.
The upgrade in the price target by Stifel reflects a strong confidence in Tandem Diabetes Care's future performance. This analyst endorsement typically leads to increased investor confidence and can drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100